Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a regional IDOR location label for Rio de Janeiro and noted NIH funding. Removed the longer 'Instituto D Or de Pesquisa e Ensino IDOR' name, and updated the page revision to v3.6.6.SummaryDifference0.1%

- Check23 days agoChange DetectedAdded Moscow, Russia (postal code 121205) as a study location and inserted new dates 2026-07-30, 2026-08-20, and 2028-02-16; Removed Krasnogorsk, Russia (postal code 143423) and earlier dates 2026-07-02, 2026-07-06, and 2027-11-30.SummaryDifference0.2%

- Check37 days agoChange DetectedThe page shows Revision: v3.6.5, indicating a new revision of the study record. This appears to be an internal maintenance update rather than a change to the study details or how the page functions.SummaryDifference15%

- Check51 days agoChange DetectedFooter revision label updated to Revision: v3.6.4, signaling a minor version update to the site's template without altering content.SummaryDifference0.0%

- Check66 days agoChange DetectedThree new date values (2026-07-06, 2026-07-02, 2026-07) were added to the page, representing recent update timestamps in the study record.SummaryDifference0.1%

- Check73 days agoChange DetectedA new page revision label v3.6.3 was added and the previous v3.6.2 label was removed, indicating a newer revision of the page metadata.SummaryDifference0.0%

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.